Most recent by Susan Kaech, PhD
SPONSORED CONTENT
October 09, 2023
4 min read
Save
Anti-CTLA-4 immune checkpoint inhibitor may hold promise for glioblastoma treatment
Researchers at Salk Institute for Biological Studies have achieved promising results in early studies using an anti-CTLA-4 antibody for treatment of glioblastoma, the most common and deadliest form of brain cancer.